Twist Biopharma Implements Genedata Biologics to Advance Synthetic Biology-driven Antibody Discovery

First-in-class software platform digitalizes Twist Biopharma’s innovative antibody lead identification and optimization SAN FRANCISCO–Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Twist Biopharma, a division of Twist Bioscience (NASDAQ: TWST), has adopted Genedata Biologics® to support their R&D innovation for biologics drug discovery services. In addition, Twist will use the [...]

Million Microbiome of Humans Project (MMHP) is launched, aiming to build the world’s largest human microbiome database

SHENZHEN, China — The “Million Microbiome of Humans Project” (MMHP) was officially launched at the 14th International Conference on Genomics (ICG-14). Scientistsfrom China, Sweden, Denmark, France, Latvia and other countries will cooperate in microbial metagenomic research, aiming to sequence and analyze one million microbial samples from intestines, mouth, skin, reproductive tract and other organs in the next three to five years to [...]

prismCDX Implements Ultivue’s UltiMapper™ Platform for Standardized, Comprehensive Cancer Tissue Phenotypic Characterization

SEOUL, South Korea–prismCDX, a highly specialized contract research organization announced today the selection and adoption of the UltiMapper platform to broaden its offering of translational biomedical research services. The addition of Ultivue’s highly standardized multiplex tissue marker assays enables the identification of critical cellular phenotypes and tissue marker signatures in support of translational and clinical [...]

ATCC Celebrates Building Expansion with Groundbreaking Ceremony

MANASSAS, Va. — ATCC launched its second headquarters expansion with a groundbreaking ceremony that celebrates its continued commitment to innovative science and to the global scientific enterprise and to its local community in Prince William County. The ceremony occurred 21 years – nearly to the day – after ATCC broke ground on its headquarters in November 1998. Expected [...]

Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services

Kassel, Germany and Cambridge, MA – Targos Molecular Pathology GmbH, a market leader in clinical biomarker services announced today a technology partnership with Ultivue, the innovation leader in multiplex tissue biomarker assays, to offer the biopharmaceutical industry new capabilities to improve the characterization of cancer patients’ samples selected for clinical research programs. UltiMapper multiplex immuno-histochemistry [...]

TTP Labtech further advances miniaturised molecular biology with launch of new mosquito genomics

The enhanced mosquito genomics showcases at NGS & Clinical Diagnostics Congress in London, 7-8 November 2019 The mosquito genomics instrument – front view. Click here to download. The mosquito genomics instrument – side view. Click here to download. Cambridge, UK. TTP Labtech Ltd, a global leader in the design and development of automated instrumentation and consumables for life science [...]

Genedata Expands Partnership with Boehringer Ingelheim to Digitalize Next Generation Cell Line Development

Genedata Selector® deployed to streamline complex cell line development processes Basel, Switzerland – Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced an expansion of its collaboration with Boehringer Ingelheim, a research-driven pharmaceutical company, to digitalize and automate complex cell line development processes. As part of this collaboration, Genedata Selector has been deployed [...]

Thermo Fisher Scientific Collaborates with Owlstone Medical to Advance the Identification of Novel Biomarkers

Early disease detection enabled through the discovery of biomarkers using non-invasive breath biopsy San Jose, Calif. – Thermo Fisher Scientific, the world leader in serving science, and Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, have entered into a collaborative partnership to advance the early diagnosis [...]

Technology brings university scientists unparalleled potential for chemical, biological and human disease research First commercial research instrument of its kind in the world. MILFORD, Mass.–(BUSINESS WIRE)– Aston University and Waters Corporation (NYSE: WAT) announced today the completed installation of the world’s first Waters™ SELECT SERIES™ Cyclic™ IMS (ion mobility spectrometry) mass spectrometer within the University’s School of Health and Life Sciences, where the instrument will support research into the biology of human diseases, the discovery of new therapeutics and advances in biotechnology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191107005188/en/ Waters Corporation has completed the installation of the world’s first SELECT SERIES Cyclic IMS mass spectrometer within the School of Health Sciences at Aston University (Birmingham, England). (Photo: Business Wire) Waters Corporation has completed the installation of the world’s first SELECT SERIES Cyclic IMS mass spectrometer within the School of Health Sciences at Aston University (Birmingham, England). (Photo: Business Wire) Mass spectrometry (MS) is a widely deployed analytical method used by scientists to identify and quantify molecules in a sample and determine their detailed molecular structure. For example, it can be used to more effectively identify disease biomarkers that allow for early detection. Ion mobility spectrometry is a proven technique that separates ions by their size, shape and charge. The SELECT SERIES Cyclic IMS takes ion mobility to a new level, replacing the traditional linear ion mobility region with a novel compact cyclic device. Ions traverse around the cyclic region and with every pass greater ion mobility resolution is achieved. In addition, the advanced technology enables the unique ability to perform ion mobility selection for ion mobility/ion mobility and IMSn experiments. The new instrument will be used by researchers at Aston University and across the Midland Innovation consortium to answer complex biological questions. Andrew Pitt, Professor of Pharmaceutical Chemistry & Chemical Biology, Aston University said: “We are delighted to have this new technology in our lab here at Aston; it will provide us and other researchers in the Midlands with a step change in how we conduct our research. “The new instrument is one of a relatively recent class of mass spectrometers, incorporating ion mobility, which separate molecules based not only on their mass but also by their shape. This allows us to see what is going on in biology in much more detail, including information we are able to gain from the shape of molecules that will allow us to solve much more complex questions.” Combining novel IMS capability with significantly improved mass spectrometry performance and enabling software, this platform allows leading researchers to unlock the potential in scientific discovery. Jim Langridge, Advanced MS Technologies Waters Corporation said: “Human biology is extraordinarily complex and the SELECT SERIES Cyclic IMS gives research scientists the ability to probe deeper into the chemistry and biology of human disease like never before. “By collaborating with leading researchers like Professor Pitt, we continually advance the science of mass spectrometry, accelerating their research into human health and well-being.” Aston University scientists will run a visiting researcher programme that will allow researchers from many disciplines to visit Aston and work with the first-of-its-kind SELECT SERIES Cyclic IMS instrument, exploring its unparalleled experimental potential. The journal Analytical Chemistry documented the effectiveness and power of the cyclic IMS instrument in a recent article titled: A Cyclic Ion Mobility – Mass Spectrometry System. About Aston University Founded in 1895 and a University since 1966, Aston is a long established university led by its three main beneficiaries – students, business and the professions, and our region and society. Aston University is located in Birmingham and at the heart of a vibrant city and the campus houses all the university’s academic, social and accommodation facilities for our students. Professor Alec Cameron is the Vice Chancellor & Chief Executive. About Waters Corporation Waters Corporation (NYSE: WAT), the world’s leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With approximately 7,200 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. Waters and SELECT SERIES are trademarks of Waters Corporation.

Cambridge, UK – Abcam’s new engineered knockout cell lysates enable proteomic studies by providing researchers with “true negative” controls. Acquiring reliable off-the-shelf knockout mouse models or cell lines that match specific experimental requirements can be challenging, and often need to be sourced directly from individual researchers or labs. Abcam’s newly-launched collection addresses this issue by providing access to [...]

World’s First Cyclic IMS Mass Spectrometer Installed at Aston University

Technology brings university scientists unparalleled potential for chemical, biological and human disease research First commercial research instrument of its kind in the world. MILFORD, Mass.–Aston University and Waters Corporation (NYSE: WAT) announced today the completed installation of the world’s first Waters™ SELECT SERIES™ Cyclic™ IMS (ion mobility spectrometry) mass spectrometer within the University’s School of Health and [...]

Access IBO on Knowledge Center
Register for Free Trial Login for Access

Register for Free Trial Login for Access

Lost your password? Register